Compare Amphastar Pharmaceuticals Inc (AMPH) vs Celsius Holdings, Inc. (CELH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Celsius Holdings, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Celsius Holdings, Inc. trades at $30.68 (market cap $7.82B). The key difference: Celsius Holdings, Inc. is far larger — about 9.5× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | CELH | |
|---|---|---|
Market Cap | $826.08M | $7.82B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $64.86 |
52-Week Low | $16.87 | $27.75 |
Enterprise Value | $1.22B | $9.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Celsius Holdings (CELH) trades at $30.60, showing modest daily gains amid a broader bearish technical trend. The stock demonstrates strong fundamental growth with revenue surging from $654M in 2022 to $2.52B in 2025, though net margins compressed to 4.29%. Recent quarters consistently beat EPS estimates, and analyst sentiment remains overwhelmingly bullish with a $53.30 consensus target. However, negative cash flow trends and ongoing legal investigations present headwinds.
CELH offers significant upside potential based on analyst targets and robust revenue expansion, particularly in international markets. Key risks include margin pressure, high valuation multiples, and legal overhangs from shareholder investigations. The stock's investment case hinges on sustaining growth momentum while navigating competitive and operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →
